{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:13:45Z","timestamp":1790741625368,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2014,4,25]],"date-time":"2014-04-25T00:00:00Z","timestamp":1398384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["MSRG-13-077-01-CPHPS"],"award-info":[{"award-number":["MSRG-13-077-01-CPHPS"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2014,8,15]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Brentuximab vedotin (BV) is an anti\u2010CD30 monoclonal antibody\u2010drug conjugate that was approved in 2011 for the treatment of patients with anaplastic large cell and Hodgkin lymphomas. The product label indicates that 3 patients who were treated with BV developed progressive multifocal leukoencephalopathy (PML), a frequently fatal JC virus\u2010induced central nervous system infection. Prior immunosuppressive therapy and compromised immune systems were postulated risk factors. In the current study, the authors reported 5 patients who developed BV\u2010associated PML, including 2 immunocompetent patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Case information was obtained from clinicians (4 patients) or a US Food and Drug Administration database (1 patient).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>All 5 patients had lymphoid malignancies. Two patients with cutaneous T\u2010cell lymphomas had not previously received chemotherapy. PML developed after a median of 3 BV doses (range, 2 doses\u20106 doses) and within a median of 7 weeks after BV initiation (range, 3 weeks\u201034 weeks). Presenting findings included aphasia, dysarthria, confusion, hemiparesis, and gait dysfunction; JC virus in the cerebrospinal fluid (2 patients) or central nervous system biopsy (3 patients); and brain magnetic resonance imaging scans with white matter abnormalities (5 patients). Four patients died at a median of 8 weeks (range, 6 weeks\u201016 weeks) after PML diagnosis. The sole survivor developed immune reconstitution inflammatory syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\n                      PML can develop after a few BV doses and within weeks of BV initiation. Clinicians should be aware of this syndrome, particularly when neurologic changes develop after the initiation of BV treatment. The decision to administer BV to patients with indolent cutaneous lymphomas should be based on consideration of risk\u2010benefit profiles and of alternative options.\n                      <jats:bold>\n                        <jats:italic>Cancer<\/jats:italic>\n                        2014;120:2464\u20132471\n                      <\/jats:bold>\n                      . \u00a9\n                      <jats:italic>2014 American Cancer Society<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.28712","type":"journal-article","created":{"date-parts":[[2014,4,25]],"date-time":"2014-04-25T15:20:46Z","timestamp":1398439246000},"page":"2464-2471","source":"Crossref","is-referenced-by-count":127,"title":["Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project"],"prefix":"10.1002","volume":"120","author":[{"given":"Kenneth R.","family":"Carson","sequence":"first","affiliation":[{"name":"Division of Medical Oncology Washington University School of Medicine St Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Newsome","sequence":"additional","affiliation":[{"name":"Division of Neuroimmunology and Neuroinfectious Diseases Johns Hopkins School of Medicine Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen J.","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Dermatology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania"},{"name":"Division of Medical Oncology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina D.","family":"Wagner\u2010Johnston","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Washington University School of Medicine St Louis Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"von Geldern","sequence":"additional","affiliation":[{"name":"Department of Neurology Johns Hopkins School of Medicine Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig H.","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology Memorial Sloan\u2010Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J.","family":"Moskowitz","sequence":"additional","affiliation":[{"name":"Division of Hematologic Oncology Memorial Sloan\u2010Kettering Cancer Center New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain H.","family":"Rook","sequence":"additional","affiliation":[{"name":"Division of Dermatology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania"},{"name":"Division of Medical Oncology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Jalan","sequence":"additional","affiliation":[{"name":"Division of Neurology Southern Illinois College of Medicine Springfield Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison W.","family":"Loren","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Landsburg","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Coyne","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Robert Wood Johnson School of Medicine Rutgers University Piscataway New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Tsai","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis W.","family":"Raisch","sequence":"additional","affiliation":[{"name":"University of New Mexico College of Pharmacy VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center Albuquerque New Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LeAnn B.","family":"Norris","sequence":"additional","affiliation":[{"name":"Southern Network on Adverse Reactions (SONAR) Program South Carolina College of Pharmacy Columbia South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Brandon","family":"Bookstaver","sequence":"additional","affiliation":[{"name":"Southern Network on Adverse Reactions (SONAR) Program South Carolina College of Pharmacy Columbia South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology Washington University School of Medicine St Louis Missouri"},{"name":"Department of Medicine Tulane University School of Medicine New Orleans Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Bennett","sequence":"additional","affiliation":[{"name":"Southern Network on Adverse Reactions (SONAR) Program South Carolina College of Pharmacy Columbia South Carolina"},{"name":"Arnold School of Public Health University of South Carolina Columbia South Carolina"},{"name":"Hollings Cancer Center Medical University of South Carolina Charleston South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809173391216"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/13550280290101094"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8619(18)31105-8"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20492"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00147-004-0779-3"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70161-5"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31822e55e7"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2011.07.003"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.080708.082655"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct071462"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318245d2d0"},{"key":"e_1_2_7_13_1","unstructured":"US Food and Drug Administration.FDA Public Health Advisory Updated Safety Information about Raptiva (efalizumab).fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/PublicHealthAdvisories\/ucm110605.htm. Access date."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-186999"},{"key":"e_1_2_7_15_1","unstructured":"National Cancer Institute.FDA Approval for Brentuximab Vedotin.cancer.gov\/cancertopics\/druginfo\/fda\u2010brentuximabvedotin. Accessed on March 17 2013."},{"key":"e_1_2_7_16_1","unstructured":"Adcetris (Brentuximab Vedotin) Package Insert.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125388s000 125399s000lbl.pdf. Accessed on May 14 2013."},{"key":"e_1_2_7_17_1","unstructured":"Adcetris (Brentuximab Vedotin) Package Insert.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125388s0005lbl.pdf. Accessed on May 14 2013."},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.10.1041"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2012.03.019"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.676170"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182749f17"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107829"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.142"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-038455"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1215357"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-151563"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.8.4175-4177.2005"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2013.03.009"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28712","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T22:58:30Z","timestamp":1760309910000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,25]]},"references-count":29,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2014,8,15]]}},"alternative-id":["10.1002\/cncr.28712"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28712","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718363653.793517168","asserted-by":"object"}]},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,25]]}}}